Chief Pamela who and joined me is Officer, Officer, today Great. Financial Horn; Dr. Medical Thank thanks With Commercial morning. Harford. Stephenson; you, us Albireo's this of Officer, and Chief all our have Paul our Simon to Chief you Patrick
we're the help. momentous will and Albireo striving expect a be communities XXXX year We to for that that
plans strategy our and you and success; on horizon our odevixibat; and our on plans three, the We have two, ramping like in update the fully roadmap up provide In go-to-market team development advances for the activity year: opportunities milestones to and pipeline. one, ahead. our an today's for on update share capitalize I'd for outline to on call, emerging the is major our the
a PFIC. patients with the But in patients. trial more exciting have odevixibat than We odevixibat let's a we pleased clinical the program. versus enrolled look and XX first number PEDFIC X at planned to XXX Now XX development very in are randomize pivotal patients developments of
We year. this expect data top mid line
the pharmacological the are to We immensely patients, bringing PEDFIC and PFIC who to the grateful worked us what have treatment and in option have community. first families the be the physicians towards with participated program could
At PEDFIC have have includes year. X expanded patients long-term meet did of Meanwhile, a which who've the eligibility over not enrolling the PEDFIC And patients been on to continue patients enroll we who same study. X extension X, cohort to therapy odevixibat now the time, for well over on of X the for been Cohort second open-label we criteria PFIC PEDFIC X. PEDFIC
preparing term of for XXXX. the the announcement we With approval expect will odevixibat in second evidence We're following body line patient different and top launch on fully in opportunity of data for PFIC and regulatory longer randomized, to generate PEDFIC half X broaden types. a this submission the capitalize odevixibat
receive biliary discussions of many biliary on investigational who Turning first atresia disease productive excited setting, extremely design. pleased following odevixibat to from treating a as treat is this We're the condition. we initiate this our indication, very IND trial, in of trial members program precedent ever devastating community next physician atresia, in conducted liver use to pivotal our and are clearance FDA, the biliary to drug the trial new Pivotal atresia.
approved and atresia life covered first rare XX,XXX the to colored at pharmacological is a and roughly XX,XXX intestine all patients Kasai EU clay therapy. biles of liver is biliary combined, no Virtually remove in most child which these the pediatric to as or workup, U.S. enterohepatic in children attached procedure, biochemical We are diagnosed in usually are the to is stools which with common believe month that the undergoes all. a their disease child's of there the of ultrasound After surgery immediately damage a not liver restore biliary and circulation. are and atresia, the to confirmation for
years, of serious serum very the have require XX% of of about a acids who patients in that children undergoing indicate transplant liver age XX% is bile that within history This cumulating despite a There XX. the biomarkers improvement by key survival. liver surgery, lower patients have and data that those transplant X a and liver require need are natural disease about an
who've and levels slows pharmacological acid procedure. undergone and bile randomized, sperm odevixibat biliary safety lower liver. treatment could be potentially first with atresia, a to be will the ongoing Kasai placebo in double-blind, study Both the damage children with Odevixibat a of to evaluate efficacy placebo-controlled the compared that
years common undergone the patients receive given not PEDFIC biliary alive a per The is arm XXX are per the the orally Children larger of who the approximately have months. atresia will trial efficacy day, X liver XX proportion of treatment and target with for endpoints of disease. that is who than odevixibat administered micrograms in infants, kilogram XXX more transplant treatment, enrollment with primary after two
clinical in of atresia. in data will valuable biomarkers that duration, We Both EMA orphan granted to regulators on disease given a the This biliary outcomes, stakeholders. FDA payers will odevixibat but and disease. using the desired designation at provide be helpful designs complexity modification initially other study and the and study proposed severity have shorter
are with begin conduct half XXXX. to in study trial of both to the We this and the plan ability and first initiate in -- confident our
trial as program provide the more on the will detail We progresses.
duration third plan guided program recent Now in a by of actions development initiate to Alagille syndrome the atresia pivotal end decided accelerate and trials, biliary the and regulatory to of year. odevixibat by the the we’ve
the granted FDA feedback program. our announcement gain would odevixibat expect designation PFIC the We data available quarter FDA of the Alagille orphan be this atresia to syndrome. and to in pivotal Alagille have We’ve line interaction biliary on results. top Both scheduled top between line a EMA the with the the and
data in PFIC estimated in these significant larger odevixibat roughly with generating Albireo. and X that XX,XXX a EU and the considerable to hepatologists population be biliary all syndrome, pediatric could experience will in atresia use will underway data will be U.S. pivotal in we in Phase and patient support and and participating have trials ultimately odevixibat pivotal be combined. With programs Many three physicians Alagille
go-to-market with We accelerating XXXX readiness and are success in our are in XXXX. Albireo and planning made for our in excellent work progress we activities
are key while engagement, leader reimbursement and and organization manufacturing, opinion build plan. expertise depth on key the and advocacy, pricing execute patient our focus to So of our we areas in
more Let deeply. me a through bit go these little
all, are and made X supply on manufacturing So, using registration we've and first formulation planning. excellent in stability. We're study chain the batches planned progress of our Phase in commercial
the regulatory to on and FDA be are in factor filings. with a of fall gating executing We agreed XXXX not expect for the plan the manufacturing we do
get participating site pivotal community, are in in our patient the programs. insight and which XXX the a We've approximately pediatric management treatment our mapping and this strong three continue planning interactions There same U.S with hepatologists flow. us We're better positive in of in activities and to is much help begun exercise Europe. to
access value challenge the is strong with course, effectiveness to is draft plan for evidence. industry other be arguments elements of burden of key broadly. our Of ready data. We study and impact ready on disease model, the pricing an be The and reimbursement and cost budget commenced emerging story continues to and work model,
our to grateful Advocacy designs, community to tell very feedback build pficvoices.com, which on their use and Patient develop which We're We're improvement collaboration. absolutely created patient insights provide we Association and their to The opportunity is PFIC an relationship wonderful have services continuing in story. initiatives. for patients study for to for advocacy families
pipeline. Let our an me X elobixibat, QX pleased initiated last by on with NAFLD we NASH. Phase this year, emerging our providing update first with of We're In trial close enrollment. call and rapidly
expect top by middle line year. We this data continue of to
investigating this over I XX appropriate to reminder, X NASH this proof-of-concept X like weeks. a milligram is would NAFLD, patients expectations a effect of As Phase and elobixibat study. study for the set
conducted for inhibitor, an risk patients As TB liver tolerability. in and positive in trends this GI both with markers, the factors NAFLD looking of favorable IBAT first study combination ever is we're the and NASH
Now, with XXX our Japan study to expect studied of XX year. for placebo. XX Japanese bile randomized we study, patients this acid and this of development. by studies combination weeks investigator early an information in partner, milligram a next dose in to next year addition sponsored elobixibat EA of inform the valuable data will the provide or These end will two Patients the sequestrant higher of stage be or Pharma, milligram, to sponsoring the [indiscernible] and [indiscernible], XX elobixibat,
Japanese Albireo has and the EA funded study. has U.S. the funded Pharma study larger
optimal in need of liver we Given and medical could tolerability. the for provide believe means cardiovascular approach the the NASH, balance our excellent risk with unmet efficacy and potential
We a have data think fibrosis once is o combined inflammation, Elobixibat absorption. elevated risks and bile mineral showing with hallmarks lipid, that effect of IBAT and easily all have and also can it promising acid, liver NASH positive inhibitors daily NASH. systemic be we preclinical clinical glucose, has liver cardiovascular on oral compound other the products. that
program from for the data strong the NASH opportunities. create believe our partnering NAFLD/NASH could we studies, value With two potential
preclinical excited progress are compounds. and our making innovation drive continue also We to be with
acid bile a and Our build new to offer modulation can therapeutic compounds our in develop than expertise wider focus has window that IBAT inhibitors. been on
file candidate more up complete the pleased a speak to expect productive this our study lead forward to the new are approach to very select curve enabling and our on IND progresses. from plan We're We as patents for new bringing and year this looking year. to about compound library,
are steps new competing for evaluating bile this priorities, have pleased we're but with for malabsorption, AXXXX,which we're acid for last, next So we to patent program. issue, developing
we year tremendous I hope referring detail, and After a in you can why the momentous Pharma. began pipeline about I excited for progress, greater as a odevixibat potential today's Albireo to are call that so XXXX. for see by reviewing XXXX
pleasure the update. my for a to it's financial please. call turn over to Simon that, with So Simon,
